KR20040084909A - 인터루킨 12 및 IFNγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제 - Google Patents

인터루킨 12 및 IFNγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제 Download PDF

Info

Publication number
KR20040084909A
KR20040084909A KR10-2004-7012557A KR20047012557A KR20040084909A KR 20040084909 A KR20040084909 A KR 20040084909A KR 20047012557 A KR20047012557 A KR 20047012557A KR 20040084909 A KR20040084909 A KR 20040084909A
Authority
KR
South Korea
Prior art keywords
ring
group
alkanediyl
alkyl
substituted
Prior art date
Application number
KR10-2004-7012557A
Other languages
English (en)
Korean (ko)
Inventor
토르스텐 블루메
볼프-디에트리히 되케
볼프강 할프브롯
요아힘 쿤케
우르술라 뫼닝
번드 엘거
허버트 슈나이더
Original Assignee
쉐링 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 악티엔게젤샤프트 filed Critical 쉐링 악티엔게젤샤프트
Publication of KR20040084909A publication Critical patent/KR20040084909A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2004-7012557A 2002-02-15 2003-01-17 인터루킨 12 및 IFNγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제 KR20040084909A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10207843A DE10207843A1 (de) 2002-02-15 2002-02-15 Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
DE10207843.2 2002-02-15
PCT/EP2003/000467 WO2003068225A1 (de) 2002-02-15 2003-01-17 Mikroglia-inhibitoren zur unterbrechung von interleukin 12 und ifn-gamma vermittelten immunreaktionen

Publications (1)

Publication Number Publication Date
KR20040084909A true KR20040084909A (ko) 2004-10-06

Family

ID=27674912

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7012557A KR20040084909A (ko) 2002-02-15 2003-01-17 인터루킨 12 및 IFNγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제

Country Status (21)

Country Link
EP (1) EP1474138A1 (sr)
JP (1) JP2005522447A (sr)
KR (1) KR20040084909A (sr)
CN (1) CN1756546A (sr)
AR (1) AR039556A1 (sr)
AU (1) AU2003245523A1 (sr)
BR (1) BR0307706A (sr)
CA (1) CA2475770A1 (sr)
DE (1) DE10207843A1 (sr)
EC (1) ECSP045297A (sr)
MX (1) MXPA04007943A (sr)
NO (1) NO20043840L (sr)
PE (1) PE20030906A1 (sr)
PL (1) PL371327A1 (sr)
RS (1) RS71304A (sr)
RU (1) RU2004127677A (sr)
TW (1) TW200306823A (sr)
UA (1) UA81111C2 (sr)
UY (1) UY27662A1 (sr)
WO (1) WO2003068225A1 (sr)
ZA (1) ZA200407382B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
WO2006097547A1 (es) * 2005-03-17 2006-09-21 Proyecto De Biomedicina Cima S.L. Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
PL3371190T3 (pl) 2015-11-06 2022-11-07 Incyte Corporation Związki heterocykliczne jako inhibitory pi3k-gamma
PL3390367T3 (pl) * 2015-12-15 2021-03-08 The Board Of Trustees Of The Leland Stanford Junior University Sposób zapobiegania zaburzeniom poznawczym związanym z wiekiem i zapaleniu tkanki nerwowej lub ich leczenia
AR107293A1 (es) 2016-01-05 2018-04-18 Incyte Corp COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
JP7244504B2 (ja) 2017-10-18 2023-03-22 インサイト・コーポレイション PI3K-γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体
CR20210165A (es) 2018-09-05 2021-10-01 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico
FI3860998T3 (fi) 2018-10-05 2024-03-27 Annapurna Bio Inc Yhdisteitä ja koostumuksia apj-reseptorin aktiivisuuteen liittyvien tautitilojen hoitoon
CN112341451B (zh) * 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341450B (zh) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4330959A1 (de) * 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
MXPA02005742A (es) * 2000-01-14 2002-09-18 Schering Ag 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia.
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10135050A1 (de) * 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
AR039556A1 (es) 2005-02-23
NO20043840L (no) 2004-11-12
UY27662A1 (es) 2003-09-30
DE10207843A1 (de) 2003-09-04
ZA200407382B (en) 2005-09-14
EP1474138A1 (de) 2004-11-10
CN1756546A (zh) 2006-04-05
JP2005522447A (ja) 2005-07-28
ECSP045297A (es) 2004-10-26
CA2475770A1 (en) 2003-08-21
MXPA04007943A (es) 2004-11-26
WO2003068225A1 (de) 2003-08-21
TW200306823A (en) 2003-12-01
BR0307706A (pt) 2005-01-11
RU2004127677A (ru) 2005-06-10
UA81111C2 (en) 2007-12-10
PE20030906A1 (es) 2004-01-17
PL371327A1 (en) 2005-06-13
RS71304A (en) 2006-10-27
AU2003245523A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
KR20040084909A (ko) 인터루킨 12 및 IFNγ에 의하여 유도되는 면역 반응을차단하기 위한 소교세포 억제제
KR20120096540A (ko) 인돌 화합물 및 그의 의약 용도
JP2007277257A (ja) ノシセプチン受容体親和性を有するベンズイミダゾール化合物
WO2000035911A1 (en) Heteroaryl-cyclic acetals
EP0797448B1 (en) Combination preparation, containing cyclosporin a or fk506 or rapamycin and a xanthine derivative
PL185526B1 (pl) Nowe pochodne (R)-(-)-metylofenylooksazolidynonu oraz środek leczniczy
EP4144728A1 (en) Heterocycle and glutarimide skeleton-based compound and applications thereof
AU2021297216A1 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
JP2006522128A (ja) 代謝調節型グルタミン酸受容体−5のモジュレーターとしての4環イミダゾール誘導体
US20060211690A1 (en) Microglia inhibitors for interrupting interleukin 12 and IFNgamma-mediated immune reactions
US20040106622A1 (en) Aryl-substituted alicylic compound and medical composition comprising the same
US7683081B2 (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
JP2006199656A (ja) アミド基を有する環状アミン化合物
KR101027556B1 (ko) 1-페닐-2-헤테로아릴-치환된 벤즈이미다졸 유도체, 면역질환의 치료용 약제를 생산하기 위한 그의 용도
JP2015040179A (ja) 免疫抑制剤
JP2005336173A (ja) 骨粗鬆症治療剤
EP1607091B1 (en) Antihepatitis c virus agent and anti-hiv agent
JP2021147322A (ja) ステロイド系化合物及びその医薬用途
JP2023518187A (ja) カルボラン及びカルボラン類似体を使用したt細胞活性化の調節方法
DE10163595A1 (de) In 3-Position heterocyclisch substituierte Piperidin-2,6-dione
JPH09176007A (ja) インターロイキン−5産生抑制剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application